Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

NCT01730118 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer
Adenocarcinomas
Metastatic Solid Tumors Characterized by HER2/Neu Expression

Interventions

BIOLOGICAL: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine

Sponsor

National Cancer Institute (NCI)